How is the Soliris Market Poised for Growth: Trends and Opportunities Through 2034
Enjoy a flat 15% OFF on all 2025 Global Market Reports until March 31st! Use code FY25SAVE to save big—don’t miss out!
How has the soliris market grown over the years?
In recent times, there has been substantial growth in the Soliris market size. The market is projected to escalate from a size of $1,880.37 million in 2024 to $2,030.44 million in 2025, exhibiting a compound annual growth rate (CAGR) of 8.0%. Factors such as regulatory endorsements, heightened awareness of rare diseases, rising demand for complement inhibition, broader indications, and an increase in diagnosis rates contributed to this growth during the historic period.
What Is the forecasted market size and growth rate for the soliris market?
The market size for soliris is forecasted to experience significant expansion in the coming years, reaching a size of $3,734.88 million by 2029, with a compound annual growth rate (CAGR) of 7.7%. Factors contributing to growth during the forecast period include an increased incidence of complement-mediated diseases, breakthroughs in gene therapy, wider market access in developing regions, the proliferation of biosimilars, and better patient adherence. Major trends projected for the forecast period encompass the adoption of combined therapies, the emergence of patient-centric treatment models, a move towards personalized medicine, the increasing installation of digital health technology, and a focus on cost-effectiveness and value-based care.
Get your soliris market report here!
https://www.thebusinessresearchcompany.com/report/soliris-global-market-report
What are the major factors driving growth in the soliris market?
Growing rates of uncommon blood conditions are anticipated to drive the expansion of the Soliris market. These rare blood diseases, like hemophilia, sickle cell anemia, and thalassemia, impact the creation, composition, or coagulation of blood. Enhanced diagnostic methods, increased awareness, and genetic and environmental influences contribute to the upsurge in such diseases. Soliris, by hindering the complement protein C5, assists patients of rare blood conditions by halting undue complement activation. This decreases the chances of severe side effects like hemolysis and organ damage, thus enhancing disease control and patient results. For instance, around 17,000 people in England were living with sickle cell disease, a genetically passed on blood disorder, as reported by the National Health Service (NHS) England in May 2024. There are about 250 fresh diagnoses every year. Consequently, the growing rates of uncommon blood ailments are propelling the expansion of the Soliris market. The escalation of the Soliris market is expected to also be fueled by increasing funds for rare disease research. The surge in investment in the research of rare diseases is stimulated by the growing acknowledgment of unmet healthcare needs, developments in genomics, and the potential for revolutionary therapies to enhance patient results. By broadening the comprehension of neglected conditions, investment in rare disease research benefits Soliris, leading to an amplified need for effective remedies. For example, the Department of Health and Science Care in the UK offered substantial financing in July 2023, including USD 834.20 million (£790 million) to Biomedical Research Centers, $15.06 million (£12 million) to the UK Rare Disease Research Platform, and $50.20 million (£40 million) to the NIHR BioResource to correlate genetic information to clinical features across 50 rare diseases, thereby boosting diagnostic and treatment development. Therefore, the growth of the Soliris market is facilitated by the increasing funds for rare disease research.
What key areas define the segmentation of the global soliris Market?
The solirismarket covered in this report is segmented –
1) By Type: Plasma Exchange; Plasma Infusion
2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH); Atypical Hemolytic Uremic Syndrome (AHUS)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp
What are the top market players propelling the growth of the soliris industry?
Major companies operating in the soliris market include Pfizer
What are the key trends shaping the future of the soliris market?
The primary trend emerging in the Soliris market is the focus on producing biologic drugs for treatment of neuromyelitis optica spectrum disorder (NMOSD), with a goal to improve therapeutic techniques for uncommon blood conditions. This indicates a notable progress in managing NMOSD, a rare and severe autoimmune ailment that affects the central nervous system, by offering effective medication to minimize relapses and prevent future nerve damage. For example, in October 2023, AstraZeneca PLC, a pharmaceutical company headquartered in the UK, secured approval for Soliris (eculizumab) from China’s National Medical Products Administration (NMPA) aimed at treating adults suffering from neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This signifies the first and unique instance where a complement inhibitor has been approved for treating NMOSD in China.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19933
What regions are dominating the soliris market growth?
North America was the largest region in the Soliris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2025
Hemoglobinopathies Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hemoglobinopathies-treatment-global-market-report
ACE Inhibitors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
